Denmark: These 56 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: capsaicin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: Denmark Patent 1,613,297

QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.

This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA

See drug price trends for QUTENZA.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Denmark Patent 1,617,832

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Denmark Patent 2,316,456

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Denmark Patent 1,622,880

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: Denmark Patent 1,629,007

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Denmark Patent 1,633,336

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Denmark Patent 1,638,551

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: Denmark Patent 2,116,227

ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Denmark Patent 1,654,263

JANUMET is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET

See drug price trends for JANUMET.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Denmark Patent 1,654,263

JANUMET XR is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR

See drug price trends for JANUMET XR.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Denmark Patent 1,654,263

JANUVIA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and one Paragraph IV challenge. Twelve tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA

See drug price trends for JANUVIA.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Denmark Patent 1,654,263

JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Denmark Patent 1,646,389

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

Generic name: elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Denmark Patent 1,646,389

ORILISSA is a drug marketed by Abbvie Inc. There are six patents protecting this drug.

This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

Generic name: cariprazine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Denmark Patent 1,663,996

VRAYLAR is a drug marketed by Allergan. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Denmark Patent 2,107,069

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Denmark Patent 2,275,439

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Denmark Patent 2,107,069

TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Denmark Patent 2,275,439

TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Denmark Patent 2,107,069

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Denmark Patent 2,275,439

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin lispro recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Denmark Patent 1,656,170

HUMALOG KWIKPEN is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG KWIKPEN

See drug price trends for HUMALOG KWIKPEN.

The generic ingredient in HUMALOG KWIKPEN is insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro recombinant profile page.

Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Denmark Patent 1,656,170

HUMALOG MIX 50/50 KWIKPEN is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 50/50 KWIKPEN

The generic ingredient in HUMALOG MIX 50/50 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.

Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Denmark Patent 1,656,170

HUMALOG MIX 75/25 KWIKPEN is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 75/25 KWIKPEN

The generic ingredient in HUMALOG MIX 75/25 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.

Generic name: insulin recombinant human; insulin susp isophane recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Denmark Patent 1,656,170

HUMULIN 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN 70/30

The generic ingredient in HUMULIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.

Generic name: insulin susp isophane recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Denmark Patent 1,656,170

HUMULIN N is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN N

See drug price trends for HUMULIN N.

The generic ingredient in HUMULIN N is insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin susp isophane recombinant human profile page.

Generic name: insulin human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Denmark Patent 1,656,170

HUMULIN R is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN R

See drug price trends for HUMULIN R.

The generic ingredient in HUMULIN R is insulin human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin human profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Denmark Patent 1,660,482

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Denmark Patent 2,060,569

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: fluticasone propionate; salmeterol xinafoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2023
Generic Entry Controlled by: Denmark Patent 1,699,434

AIRDUO RESPICLICK is a drug marketed by Teva Pharm. There are sixteen patents protecting this drug.

This drug has four hundred and nineteen patent family members in thirty-seven countries. There has been litigation on patents covering AIRDUO RESPICLICK

The generic ingredient in AIRDUO RESPICLICK is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

Generic name: ciclesonide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 16, 2023
Generic Entry Controlled by: Denmark Patent 1,670,482

ALVESCO is a drug marketed by Covis. There is one patent protecting this drug.

This drug has fourteen patent family members in twelve countries.

See drug price trends for ALVESCO.

The generic ingredient in ALVESCO is ciclesonide. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciclesonide profile page.

Generic name: ciclesonide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 16, 2023
Generic Entry Controlled by: Denmark Patent 1,670,482

OMNARIS is a drug marketed by Covis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fourteen patent family members in twelve countries.

See drug price trends for OMNARIS.

The generic ingredient in OMNARIS is ciclesonide. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciclesonide profile page.

Generic name: ciclesonide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 16, 2023
Generic Entry Controlled by: Denmark Patent 1,670,482

ZETONNA is a drug marketed by Covis. There is one patent protecting this drug.

This drug has fourteen patent family members in twelve countries.

See drug price trends for ZETONNA.

The generic ingredient in ZETONNA is ciclesonide. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciclesonide profile page.

Generic name: cabazitaxel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Denmark Patent 1,667,986

JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.

Generic name: telavancin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: Denmark Patent 1,678,201

VIBATIV is a drug marketed by Cumberland Pharms. There are three patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in thirty-five countries.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.

Generic name: telavancin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: Denmark Patent 2,495,251

VIBATIV is a drug marketed by Cumberland Pharms. There are three patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in thirty-five countries.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.

Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: Denmark Patent 1,677,792

DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT

See drug price trends for DUETACT.

The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

Generic name: sapropterin dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: Denmark Patent 1,708,690

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

Generic name: sapropterin dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: Denmark Patent 3,138,566

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Denmark Patent 1,687,019

SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Denmark Patent 3,300,721

SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Denmark Patent 1,687,019

VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Denmark Patent 3,300,721

VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Denmark Patent 1,689,370

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: latanoprostene bunod
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Denmark Patent 1,704,141

VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Denmark Patent 1,874,282

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: fosdenopterin hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Denmark Patent 1,664,317

NULIBRY is a drug marketed by Sentynl Theraps Inc. There is one patent protecting this drug.

This drug has ten patent family members in ten countries.

The generic ingredient in NULIBRY is fosdenopterin hydrobromide. One supplier is listed for this generic product. Additional details are available on the fosdenopterin hydrobromide profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Denmark Patent 1,945,632

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Denmark Patent 2,395,002

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Denmark Patent 2,404,919

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Denmark Patent 2,774,925

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: omega-3-carboxylic acids
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: Denmark Patent 1,755,565

EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.

This drug has eighty-four patent family members in forty countries.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.

Generic name: ospemifene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Denmark Patent 1,718,288

OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.

Generic name: lomitapide mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: Denmark Patent 1,725,234

JUXTAPID is a drug marketed by Amryt. There are eight patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

Generic name: fostemsavir tromethamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Denmark Patent 1,725,569

RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

See drug price trends for RUKOBIA.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Denmark Patent 1,730,131

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Denmark Patent 1,730,131

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: etonogestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Denmark Patent 1,729,819

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

Generic name: teriparatide recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Denmark Patent 1,732,628

FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

Generic name: teriparatide recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Denmark Patent 1,732,629

FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Denmark Patent 1,740,163

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Denmark Patent 1,740,177

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Denmark Patent 2,570,128

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Denmark Patent 1,746,999

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Denmark Patent 1,819,353

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Denmark Patent 2,030,981

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Denmark Patent 2,260,835

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Denmark Patent 2,261,236

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Denmark Patent 1,747,036

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Denmark Patent 1,747,036

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

Generic name: elvitegravir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Denmark Patent 1,636,190

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has eighty-three patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

Generic name: vandetanib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Denmark Patent 1,753,431

CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.

This drug has one hundred and forty-two patent family members in forty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Denmark Patent 1,753,406

KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Denmark Patent 2,298,288

KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

Generic name: saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Denmark Patent 1,753,406

ONGLYZA is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

Generic name: saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Denmark Patent 2,298,288

ONGLYZA is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.